Open-Label Study of Omega 3 Oil Supplementation for Aging-Related Cognitive Decline

Completed · Not applicable

Conditions studied: Cognitive Decline

In brief

Aging-related cognitive decline may be affected by brain cholesterol and the health of cell membranes. Certain nutritional supplements have been proposed to support membrane health, and there is increasing interest in plasmalogens and Omega-3 derived oil supplements to support brain health among older adults. The product being investigated in this study is the ProdromeNeuro Omega 3 oil nutritional supplement. This product contains naturally occurring fatty acids in higher concentrations than similar products that are commercially available. The purpose of this research study is to better understand the effects of ProdromeNeuro Omega-3 nutritional supplementation among subjects with age-related cognitive decline.

Key facts

Study ID

NCT04484454

Run by

Neurological Associates of West Los Angeles

People needed

20

Starts

2020-07-17

Expected to finish

2021-03-13

Last updated by the study team

2021-06-07

Who can join

Age: 35 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Cognitive decline due to aging-related changes
• Clinical Dementia Rating stage of mild dementia 0.5 through moderate dementia CDR stages 1 and 2

You may not qualify if…

• Subjects unable to give informed consent
• Cognitive decline clearly related to an acute illness
• Subjects taking anticoagulants and anti-platelet agents
• Advanced terminal illness
• Any active cancer or chemotherapy
• Any other neoplastic illness or illness characterized by neovascularity

Where it is running

• Neurological Associates of West Los Angeles — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.